Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Hair loss and fatigue are both reported with tirzepatide, though hair thinning is not a common, direct side effect and is more often linked to rapid weight loss, nutritional gaps, or stress on the hair growth cycle, while fatigue can stem from reduced calorie intake, dehydration, low blood sugar, or nausea; there are several important factors to consider, so see below for the full picture. Timing matters too, since hair shedding often appears months after weight loss begins and usually improves, whereas persistent or severe fatigue may point to something else that needs evaluation. Adequate protein, iron, vitamin D, B12, fluids, and a slower rate of weight loss are commonly discussed strategies, and details on each are outlined below. Because these symptoms overlap with thyroid problems, anemia, depression, and other conditions, self-diagnosis can be misleading.
If you are unsure whether your hair loss or exhaustion is a passing medication effect or a sign of something that deserves attention, a free, instant, online symptom check can help you organize your symptoms, see possible explanations, and understand which next steps or specialist visits make sense.
Last reviewed for medical accuracy: 09/12/2026
Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (as Mounjaro®) and chronic weight management (as Zepbound®). Like all medications, it can cause side effects. Two concerns patients sometimes raise are hair loss and fatigue. Here’s an evidence-based look at what’s known—and what you can do.
Overview of Tirzepatide Side Effects
Clinical trials and the FDA prescribing information list the most common adverse reactions:
• Gastrointestinal (GI) symptoms
– Nausea (up to 40–50% in early weeks)
– Diarrhea (20–40%)
– Vomiting (10–30%)
– Constipation (10–20%)
– Abdominal pain, dyspepsia, gastroesophageal reflux
• Decreased appetite
• Injection-site reactions (mild redness or itching)
• Hypoglycemia (when used with insulin or sulfonylureas)
Less common reactions include acute kidney injury (mostly in the context of dehydration from GI upset), gallbladder disease, and pancreatitis. Hair loss and fatigue are not highlighted as primary risks in the official label, but some patients do report them. Let’s dig deeper.
Hair Loss: What the Evidence Says
Not a labeled adverse reaction
• The FDA prescribing information for tirzepatide does not list hair loss (alopecia) among common or serious side effects.
• Large phase 3 trials (SURPASS and others) did not record significant rates of hair thinning linked directly to the drug.
Possible indirect factors
• Rapid weight loss. Losing weight quickly can sometimes trigger telogen effluvium, a temporary increase in hair shedding as follicles shift from growth to rest phase.
• Nutritional changes. Caloric restriction or dietary shifts can lead to deficiencies (iron, zinc, biotin) that affect hair health.
• Stress on the body. Adjusting to a new medication, especially if GI side effects occur, can be physically taxing.
Anecdotal reports
• In online patient forums, a small number of people on tirzepatide mention noticing thinner hair after 2–6 months.
• Case reports in medical literature remain scarce.
What you can do
• Monitor your nutritional status. Ensure adequate protein, iron, zinc and B-vitamins.
• Talk to your doctor about checking ferritin, vitamin D, thyroid function.
• Practice gentle hair care: avoid tight hairstyles, heat styling, harsh chemicals.
• If hair loss persists or worsens, seek evaluation by a dermatologist.
Bottom line: Hair loss isn’t a well-documented direct effect of tirzepatide, but rapid weight loss and related nutritional factors may play a role. Staying on top of your diet and lab tests is key.
Fatigue: Causes and Considerations
Reported rates in trials
• In clinical trials, fatigue was noted in a minority of participants (generally <5% across doses).
• Often these reports occurred early, during dose escalation weeks.
Potential explanations
• GI side effects. Ongoing nausea, vomiting or diarrhea can lead to dehydration and electrolyte imbalances, causing tiredness.
• Reduced calorie intake. As appetite decreases, you may eat less. If overall calories or key nutrients drop too low, fatigue can follow.
• Blood sugar swings. Although tirzepatide improves glycemic control, combining it with other glucose-lowering drugs can raise the risk of hypoglycemia if dosing isn’t adjusted. Low blood sugar often manifests as weakness and fatigue.
• Adjustment period. Starting any new medication can temporarily affect energy levels as your body adapts.
Management tips
• Stay hydrated. Drink water consistently throughout the day—especially if you have diarrhea or vomiting.
• Monitor blood sugars. If you’re diabetic, check frequently during dose changes and work with your provider to adjust insulin or sulfonylurea doses.
• Balance meals. Focus on protein, fiber and healthy fats to maintain satiety and steady energy.
• Get adequate rest. If you feel unusually tired, allow time for extra rest and avoid overexertion.
• Report persistent fatigue to your doctor. It may signal other issues (anemia, thyroid problems, or rarely more serious effects).
Putting It All Together
Most patients tolerate tirzepatide well, with gastrointestinal discomfort being the main hurdle. Hair loss and fatigue are not among the top listed side effects, but can occur indirectly through rapid weight loss, dietary changes, dehydration or hypoglycemia. Here’s a quick checklist:
• Track your symptoms. Note when hair shedding or tiredness starts and whether it coincides with dose changes.
• Review your nutrition. Ensure you’re getting enough calories, protein and micronutrients.
• Stay hydrated. Replace fluids and electrolytes lost to GI side effects.
• Monitor blood sugar. Work with your diabetes care team to prevent lows.
• Practice gentle self-care. Stress reduction, good sleep hygiene and scalp-friendly hair practices help.
If you experience concerning symptoms, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to get tailored guidance on when to seek medical care.
When to Speak to a Doctor
Always seek prompt medical attention if you have:
• Severe or persistent vomiting/diarrhea
• Signs of dehydration (dizziness, dark urine, rapid heart rate)
• Hypoglycemia that doesn’t respond to quick sugar sources
• Unexplained weight loss beyond what’s expected
• Sudden, widespread hair loss or scalp issues
And if fatigue is so severe that it interferes with daily life or is accompanied by chest pain, shortness of breath, or fainting, contact a healthcare professional immediately.
Final Thoughts
Tirzepatide can be a powerful tool for managing diabetes and supporting weight loss. While hair loss and fatigue aren’t common, they can emerge indirectly. Staying informed, maintaining good nutrition and hydration, and monitoring blood sugars go a long way toward minimizing these issues. Always keep an open line of communication with your healthcare team—and if any symptom feels serious or life-threatening, speak to a doctor right away.
(References)
* Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2. Epub 2024 May 21. PMID: 38770818; PMCID: PMC11106805.
* Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025 May;92(5):1141-1143. doi: 10.1016/j.jaad.2025.01.046. Epub 2025 Jan 23. PMID: 39863171.
* Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, Stegura C, Wine Lee L. A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J Drugs Dermatol. 2025 Apr 1;24(4):413-415. doi: 10.36849/JDD.8605. PMID: 40196945.
* Rojas Lopez RF, Lynett Barrera D, Amaya Muñoz MC, Saavedra Diaz MP. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025 Aug;17(8):e90021. doi: 10.7759/cureus.90021. Epub 2025 Aug 13. PMID: 40951222; PMCID: PMC12431796.
* Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, Zamandar A, Alkhames S. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025 Sep;17(9):e92454. doi: 10.7759/cureus.92454. Epub 2025 Sep 16. PMID: 41111833; PMCID: PMC12530271.
* Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. J Am Acad Dermatol. 2026 Jun;94(6):1826-1827. doi: 10.1016/j.jaad.2026.02.042. Epub 2026 Feb 17. PMID: 41707704.
* Lee N, Kim Y. Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes Metab Res Rev. 2026 May;42(4):e70163. doi: 10.1002/dmrr.70163. PMID: 41886296; PMCID: PMC13020769.
* Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Epub 2026 Mar 28. PMID: 41903163.
* Parizad R, Hatwal J, Taban Sadeghi M, Brar A, Desai R, Batta A, Mohan B. Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence. Vasc Health Risk Manag. 2026;22:578698. doi: 10.2147/VHRM.S578698. Epub 2026 Mar 10. PMID: 41953528; PMCID: PMC13054715.
* Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026 Apr-Jun;109(2):368504261444578. doi: 10.1177/00368504261444578. Epub 2026 Apr 17. PMID: 41998799; PMCID: PMC13100445.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.